Aceto Corporation (ACET): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACET POWR Grades
- ACET scores best on the Value dimension, with a Value rank ahead of 60.75% of US stocks.
- The strongest trend for ACET is in Growth, which has been heading down over the past 179 days.
- ACET's current lowest rank is in the Stability metric (where it is better than 3.08% of US stocks).
ACET Stock Summary
- ACET's price/sales ratio is 28.62; that's higher than the P/S ratio of 95.12% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for ADICET BIO INC; that's greater than it is for just 9.12% of US stocks.
- Revenue growth over the past 12 months for ADICET BIO INC comes in at 214.91%, a number that bests 95.92% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ACET, based on their financial statements, market capitalization, and price volatility, are ACRS, CCCC, STOK, MRTX, and CARA.
- Visit ACET's SEC page to see the company's official filings. To visit the company's web site, go to www.restorbio.com.
ACET Valuation Summary
- In comparison to the median Healthcare stock, ACET's EV/EBIT ratio is 222.37% lower, now standing at -9.3.
- Over the past 58 months, ACET's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ACET.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACET | 2022-11-01 | 20.1 | 2.3 | -14.2 | -9.3 |
| ACET | 2022-10-31 | 19.5 | 2.3 | -13.8 | -8.9 |
| ACET | 2022-10-28 | 20.3 | 2.3 | -14.4 | -9.4 |
| ACET | 2022-10-27 | 19.1 | 2.2 | -13.6 | -8.6 |
| ACET | 2022-10-26 | 20.0 | 2.3 | -14.2 | -9.2 |
| ACET | 2022-10-25 | 19.2 | 2.2 | -13.6 | -8.7 |
ACET's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACET has a Quality Grade of D, ranking ahead of 8.53% of graded US stocks.
- ACET's asset turnover comes in at 0.043 -- ranking 330th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ACET's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.043 | 1 | -1.841 |
| 2021-03-31 | 0.027 | 1 | -2.369 |
| 2020-12-31 | 0.157 | 1 | -2.317 |
| 2020-09-30 | 0.031 | 1 | -3.142 |
| 2020-06-30 | 0.000 | NA | -1.790 |
| 2020-03-31 | 0.000 | NA | -1.243 |
ACET Price Target
For more insight on analysts targets of ACET, see our ACET price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $28.29 | Average Broker Recommendation | 1.21 (Strong Buy) |
ACET Stock Price Chart Interactive Chart >
ACET Price/Volume Stats
| Current price | $17.15 | 52-week high | $21.87 |
| Prev. close | $17.20 | 52-week low | $9.29 |
| Day low | $16.65 | Volume | 277,900 |
| Day high | $17.23 | Avg. volume | 499,140 |
| 50-day MA | $16.53 | Dividend yield | N/A |
| 200-day MA | $15.27 | Market Cap | 734.89M |
Aceto Corporation (ACET) Company Bio
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.
Latest ACET News From Around the Web
Below are the latest news stories about ADICET BIO INC that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Bio Inc. (ACET) is an excellent investment, but the stock is overvalued/undervalued right nowIn Monday’s session, Adicet Bio Inc. (NASDAQ:ACET) marked $20.74 per share, down from $21.27 in the previous session. While Adicet Bio Inc. has underperformed by -2.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACET rose by 112.72%, with highs and lows ranging from $21.87 to […] |
Analysts Conflicted on These Healthcare Names: Adicet Bio (ACET) and Terns Pharmaceuticals (TERN)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adicet Bio (ACET – Research Report) and Terns Pharmaceuticals (TERN – Research Report). Adicet Bio (ACET) JMP Securities analyst Reni Benjamin reiterated a Buy rating on Adicet Bio today and set a price target of $21.00. The company's shares closed last Thursday at $20.78, close to its 52-week high of $21.21. According to TipRanks. |
Adicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)Adicet Bio ( NASDAQ:ACET ) Third Quarter 2022 Results Key Financial Results Net loss: US$22.0m (loss widened by 57... |
Adicet Bio (ACET) Receives a Buy from JonesTradingIn a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Adicet Bio (ACET - Research Report), with a price target of $25.00. The company's shares opened today at $20.00.According to TipRanks, Roy is a 4-star analyst with an average return of 8.3% and a 34.17% success rate. Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and Day One Biopharmaceuticals.Currently, the analyst consensus on Adicet Bio is a Strong Buy with an average price target of $27.40, representing a 37.00% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target. |
Adicet Reports Third Quarter 2022 Financial Results and Provides Business UpdatesREDWOOD CITY, Calif. & BOSTON, November 08, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2022. |
ACET Price Returns
| 1-mo | -0.23% |
| 3-mo | 19.93% |
| 6-mo | 45.09% |
| 1-year | 82.45% |
| 3-year | 102.48% |
| 5-year | N/A |
| YTD | -1.94% |
| 2021 | 24.48% |
| 2020 | 34.71% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...